Results 351 to 360 of about 181,705 (382)
Some of the next articles are maybe not open access.
Annual Review of Biochemistry, 1992
The biochemistry of amyloidosis as it relates to clinical medicine and experimental pathology is presented. Amyloidoses are complex disorders in which normally soluble precursors undergo pathological conformational changes and polymerize as insoluble fibrils with the beta-pleated sheet conformation.
Jean D. Sipe, A. S. Cohen
openaire +5 more sources
The biochemistry of amyloidosis as it relates to clinical medicine and experimental pathology is presented. Amyloidoses are complex disorders in which normally soluble precursors undergo pathological conformational changes and polymerize as insoluble fibrils with the beta-pleated sheet conformation.
Jean D. Sipe, A. S. Cohen
openaire +5 more sources
Orvosi Hetilap, 2010
Amyloidosis is the clinical condition caused by extracellular deposition of amyloid in the tissues. Amyloid deposits are composed of amyloid fibrils, abnormal insoluble protein fibres formed by misfolding of their normally soluble precursors. About 30 different proteins can form clinically or pathologically significant amyloid fibrils in vivo as a ...
M.B. Pepys, Philip N. Hawkins
openaire +4 more sources
Amyloidosis is the clinical condition caused by extracellular deposition of amyloid in the tissues. Amyloid deposits are composed of amyloid fibrils, abnormal insoluble protein fibres formed by misfolding of their normally soluble precursors. About 30 different proteins can form clinically or pathologically significant amyloid fibrils in vivo as a ...
M.B. Pepys, Philip N. Hawkins
openaire +4 more sources
Best Practice & Research Clinical Haematology, 2005
Amyloidosis is an uncommon plasma-cell dyscrasia with an incidence of eight patients per million per year. It is often difficult to recognize because of the myriad symptoms and vague nature of the clinical presentation. Symptoms include fatigue, dyspnea, edema, paresthesias, and weight loss.
Morie A, Gertz +3 more
openaire +3 more sources
Amyloidosis is an uncommon plasma-cell dyscrasia with an incidence of eight patients per million per year. It is often difficult to recognize because of the myriad symptoms and vague nature of the clinical presentation. Symptoms include fatigue, dyspnea, edema, paresthesias, and weight loss.
Morie A, Gertz +3 more
openaire +3 more sources
Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis
European Journal of Heart Failure, 2022Systematic evidence on the prevalence and clinical outcome of transthyretin amyloidosis (ATTR) is missing. We explored: (i) the prevalence of cardiac amyloidosis in various patient subgroups, (ii) survival estimates for ATTR subtypes, and (iii) the ...
A. Antonopoulos +9 more
semanticscholar +1 more source
Hematology/Oncology Clinics of North America, 1999
Amyloidosis is considered rare but has an incidence similar to that of Hodgkin's disease and chronic granulocytic leukemia. The diagnosis should be considered in any patient with unexplained nephrotic-range proteinuria, heart failure, peripheral neuropathy, or hepatomegaly.
Dispenzieri, A, Lacy, MQ, Gertz, MA
openaire +3 more sources
Amyloidosis is considered rare but has an incidence similar to that of Hodgkin's disease and chronic granulocytic leukemia. The diagnosis should be considered in any patient with unexplained nephrotic-range proteinuria, heart failure, peripheral neuropathy, or hepatomegaly.
Dispenzieri, A, Lacy, MQ, Gertz, MA
openaire +3 more sources
Current Treatment Options in Oncology, 2006
Amyloidosis is a disease in which abnormal proteins form fibrillar tissue deposits that can compromise key viscera and lead to early death. In order to treat amyloidosis, the type of abnormal protein must be identified. The most common type is monoclonal immunoglobulin light chain or AL amyloidosis; the other important type is hereditary, caused by ...
openaire +5 more sources
Amyloidosis is a disease in which abnormal proteins form fibrillar tissue deposits that can compromise key viscera and lead to early death. In order to treat amyloidosis, the type of abnormal protein must be identified. The most common type is monoclonal immunoglobulin light chain or AL amyloidosis; the other important type is hereditary, caused by ...
openaire +5 more sources
Current Opinion in Rheumatology, 1991
Amyloidosis is a disease involving the fibrillar deposition of proteins in a manner that uniformly leads to the presence of green birefringence on polarization microscopy after staining the involved tissues with Congo red. In the year summarized, a wide range of new information has accumulated about this disease.
A S, Cohen, L A, Jones
openaire +2 more sources
Amyloidosis is a disease involving the fibrillar deposition of proteins in a manner that uniformly leads to the presence of green birefringence on polarization microscopy after staining the involved tissues with Congo red. In the year summarized, a wide range of new information has accumulated about this disease.
A S, Cohen, L A, Jones
openaire +2 more sources
Cardiac Amyloidosis Due to Transthyretin Protein: A Review.
Journal of the American Medical Association (JAMA)Importance Systemic amyloidosis from transthyretin (ATTR) protein is the most common type of amyloidosis that causes cardiomyopathy. Observations Transthyretin (TTR) protein transports thyroxine (thyroid hormone) and retinol (vitamin A) and is ...
F. Ruberg, Mathew S. Maurer
semanticscholar +1 more source
Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review.
Journal of the American Medical Association (JAMA), 2020Importance Many patients with systemic amyloidosis are underdiagnosed. Overall, 25% of patients with immunoglobulin light chain (AL) amyloidosis die within 6 months of diagnosis and 25% of patients with amyloid transthyretin (ATTR) amyloidosis die within
M. Gertz, A. Dispenzieri
semanticscholar +1 more source
Current Opinion in Rheumatology, 1996
Developments concerning amyloidosis associated with rheumatic diseases or often causing musculoskeletal symptoms are reviewed. The pathogenesis, clinical manifestations, diagnosis, and therapy of amyloid A, amyloid light-chain, and amyloid beta 2-microglobulin amyloidosis are discussed from the standpoint of a clinical rheumatologist.
C, Friman, T, Pettersson
openaire +2 more sources
Developments concerning amyloidosis associated with rheumatic diseases or often causing musculoskeletal symptoms are reviewed. The pathogenesis, clinical manifestations, diagnosis, and therapy of amyloid A, amyloid light-chain, and amyloid beta 2-microglobulin amyloidosis are discussed from the standpoint of a clinical rheumatologist.
C, Friman, T, Pettersson
openaire +2 more sources